Background
As people age, the immune system exhibits age-associated changes resulting in impaired immunity. This so-called immune senescence is a complex multifactorial phenomenon characterized by a number of features including: i) reduced number of naïve T cells; ii) increased frequencies of differentiated CD28
-CD57
+ T cells that have a reduced proliferative capacity; iii) reduced CD4/CD8 ratio; oligoclonal expansion of CD8 T cells, and iv) progressive shortening of telomeres [
1‐
3]. Telomeres are repetitive (TTAGGG)
n nucleotide sequences that shorten with each cell division [
4]. Among people aged over 60 years, short leukocyte telomere length has been associated with higher mortality rates from infectious diseases [
5].
People who inject drugs (injecting drug users, IDU) are at increased risk of contracting both acute and chronic infections [
6,
7]. The prevalence of HCV antibodies in IDU ranges from 15–98 % [
8,
9]. Upon HCV infection, 75 % of individuals progress to chronic infection and are at risk for progressive liver disease, liver cirrhosis and hepatocellular carcinoma [
10]. The worldwide prevalence of HIV infection among IDU is estimated to be 18 % [
11]. With the advent of combination antiretroviral therapy (cART) and decline in drug-related causes of death, the mean age of IDU is increasing [
12,
13] and IDU are at premature risk of developing multimorbidity and mortality from causes commonly observed in the elderly [
14,
15].
Immunological changes and increased levels of inflammation could form the basis of this premature burden of morbidity and mortality among ageing DU. Progression of immune senescence was shown to be accelerated by chronic viral infections such as HIV through (long-term) continuous immune activation [
16,
17]. Despite adequate combination antiretroviral therapy (cART), HIV infected individuals have increased risk for non-AIDS morbidity as compared to age-matched controls [
18,
19]. There is a growing body of literature that suggests that HCV has a role in extrahepatic morbidity and mortality likely through a similar mechanism of immune activation [
20,
21]. Indeed, like HIV, HCV infection also leads to PD-1
high and TIM-3
high T cells, a phenotype associated with exhaustion due to persistent antigenic pressure [
22]. In addition to HIV and HCV monoinfection, HIV/HCV coinfected individuals do not only seem to have increased risk for liver disease progression [
23] but also progression to AIDS [
24], which suggests that both viruses could enhance each other’s disease progression [
25].
To assess the impact of an infection with HCV and HIV/HCV specifically, we studied parameters associated with immune senescence. To this end, we included IDU with HCV mono- or HIV/HCV coinfection. As a control group to control for use of cocaine, opioid and social practices connected with drug use, we studied IDU with similar injecting risk behavior that where multiple exposed but uninfected (MEU) from the Amsterdam Cohort Studies (ACS) among drug users, at two time-points during follow-up >15 years apart. To address the severity of immune senescence parameters, we compared these between the specific IDU groups and healthy individuals.
Flow cytometric analyses
Stored PBMCs were rapidly thawed and 1*106 cells were stained in PBS with 0.5 % bovine serum albumin (BSA) and 0.1 % sodium azide using combinations of the following antibodies: CD4 Pacific Blue, CD3 AlexaFluor700, HLA-DR PerCP (Biolegend), CD8 Horizon V500, CD27 APC-eFluor780 (eBioscience), CD38 PE (Caltag) and PD-1 PerCP-Cy5.5. Cells were incubated with the antibodies for 20 min at 4 °C. After washing with PBS/0.5 % BSA, cells were fixed with Cellfix (BD) and directly analyzed by flow cytometry. For each sample a minimum of 100,000 cells were acquired using a LSRII FACS (BD) and data were processed using FACSDiva 6.0 software (BD).
Flowcytometric analysis of telomere length in T cell subsets
Telomere length of PBMCs was assessed using a five color flow cytometry fluorescent in situ hybridization (flow-FISH) protocol, adapted from Baerlocher et al. [
27] Here, telomeres are hybridized to an AlexaFluor488 labeled peptide nucleic acid (PNA) telomeric (C3TA2)
3 probe and subsequently analyzed by flow cytometry. In short, stored PBMCs were rapidly thawed and 2*10
6 cells were stained with heat-stable fluorochrome-labeled antibodies for CD3 Pacific Blue (eBioscience), CD8 V500 (BD), CD27 Alexa fluor 647 (BD) and CD57-biotin (Biolegend), followed by streptavidin-Cy3 (Sigma). After washing, the cells were fixed with bis(sulfosuccinimidyl)suberate (BS
3, Pierce) for 30 min at 4 °C in the dark. Cells were washed with PBS and incubated for 10 min with an hybridization solution, with and without the PNA probe and 15 min at 82 °C to denature the DNA. After 1 h of hybridization at room temperature and in the dark, cells were washed and analyzed immediately by flow cytometry. Samples were gated on live, singlet CD3
+ T cells. Calf thymocytes were included in each experiment as an internal control. The gating strategy is shown in Additional file
2: Figure S1. Relative telomere length (RTL) of each sample was calculated as the ratio between the median fluorescent intensity (MFI) of the T cell subset of interest with probe (minus the MFI without probe) divided by the MFI of the calf thymocytes with probe (minus the MFI without probe). All experiments were performed in duplo and RTLs were averaged per sample.
Discussion
In this longitudinal study we observed significantly decreased telomere lengths among ageing HIV/HCV coinfected IDU as compared to healthy donors. In the period in which IDU had no access to cART, the impact of HIV/HCV on telomere length was noticeable already at the first timepoint in infection that we analysed, in both the CD4 and CD8 T-cell compartment with significantly reduced telomere lengths. During a period of 16 years we observed no increased decline of telomere length between the study groups. These data suggest that the lower telomere lengths were induced earlier in infection. HCV monoinfected IDU had significantly decreased telomere lengths in their CD4+ T cells, but CD8+ T cells were not affected by increased telomere erosion. Over time we observed no increase in the percentage of differentiated cells in each study group, but we did observe a continued decline of telomere erosion. Therefore it is unlikely that T-cell differentiation alone explains the continued telomere erosion. Telomere decline could be explained by increased peripheral levels of activation (HLA-DR+CD38+), mature differentiated (CD27-CD57+) cells and exhaustion (PD-1) in peripheral T cells of HCV monoinfected and HIV/HCV coinfected IDU which indicates a state of chronic immune activation.
As expected, we observed that telomere length decreased over time in all IDU groups. However this was independent of viral coinfections (HCV or HIV/HCV). Interestingly, at a relatively young age the telomere length of predominantly CD8
+ T cells, but also CD4
+ T cells, was markedly decreased in HIV/HCV coinfected individuals and was comparable to more than 15 year older healthy donors. As most HIV/HCV coinfected individuals were cART naïve early during infection, the immune system responds to HIV with high levels of activation and proliferation rates [
37]. Consequently HIV drives T cells to increasingly differentiated phenotypes that are oligoclonally expanded, less functional and more prone to apoptosis [
38]. We demonstrated that loss of telomere length is not simply due to increased differentiation but mainly to continued immune activation. Importantly, this study demonstrates that the loss in telomere length mainly occurred at the first time-point in infection that we analysed and was not restored to the level of healthy individuals with the initiation of cART. We could not rule out that cART, via telomerase inhibition [
39], negatively affects telomere length. However a recent cross-sectional study by Zanet et al. demonstrated no association between low telomere length and cART exposure [
40].
Here we found that HCV monoinfected IDU had lower CD4
+ T cell telomere lengths than healthy donors at the first timepoint in infection that we analysed, suggesting that HCV on its own may have an effect on immune senescence. However, CD8
+ T cell telomere length was not affected. Unfortunately we had no clinical outcomes to relate to, but a hospital-based study found that, independent of age, decreased CD4
+ memory telomere length was associated with increased liver fibrosis [
41]. In addition, longer CD4
+ and CD8
+ T cell telomere lengths were both associated with a sustained virological response following HCV treatment. We demonstrated that in HCV monoinfected IDU the decreased telomere length in CD4
+ T cells occurred mainly in the immature T cells. Although this population consists of both naïve and central memory cells [
42], reduced numbers of CD4 naïve T cells and reduced recent thymic emigrants have been associated with HCV infection, especially if fibrosis is present [
43,
44]. This fits with a model in which CD4
+ T cells are continuously activated during persistent HCV infection, especially when the infection aggravates.. However, due to a lack of samples we were unable to investigate the specific responses of HIV/HCV coinfected DU.
The exact mechanisms through which HIV, HCV and natural ageing collectively affect disease progression remains to be resolved. Accumulating evidence points towards a role for systemic immune senescence affecting multiple organs/tissues. Data from a recent study among IDU demonstrated that higher levels of interleukin 6, a proinflammmatory cytokine, were independently associated with HCV monoinfection, HIV/HCV coinfection and increasing age [
45]. Decreased telomere length has also been associated with atherosclerosis and cardiovascular disease, and is likely to be correlated with interleukin 6 levels [
46].
Of interest, MEU IDU tended to have lower levels of immune activation compared to healthy donors. This special group of IDU has been shown to have detectable HIV-specific [
47] and HCV-specific T-cell responses [
48], indicating their exposure to both infections. The notion of a naturally occurring resistance to certain viral pathogens has major implications for T-cell vaccine development. In a recent study though, robust activation of natural killer cells, but not HCV-specific adaptive immune responses, was associated with protection against infection with HCV among MEU DU [
49].
There were several limitations in this study. Due to instability to heat we were unable to use CD45RA and CCR7 as markers of memory and differentiation in our assay. Interestingly, it did enable us to demonstrate that loss of CD27 was significantly associated with telomere loss in both CD4
+ and CD8
+ T cell, which occurred before the upregulation of CD57 [
31].
This study is limited by the unknown duration of HIV and HCV infection. However, as the observed peak incidence of HIV in Amsterdam occurred during the 80’s [
50] we assumed that our first time point of analysis was close to the actual infection time point. For HCV the observed peak prevalence also occurred during the 80’s. We demonstrated that the reduction in telomere length already occurred at the first time-point and that we did not find any difference in the rate of telomere length decline over a period of almost 17 years between MEU, HCV monoinfected and HIV coinfected IDU. This suggests that the telomere decline occurred earlier during infection. But, we can not rule out that the HIV or HCV infected IDU had lower telomere lengths pre-acquisition of HIV or HCV. To prove our hypothesis it would be of future interest to investigate telomere decline in HIV and HCV seroconverters. Unfortunately we had no access to bloodsamples of healthy donors followed over time. Because we used different healthy donors for the two time-points the decline in RTL could be biased by inter-individual variations.
Competing interests
The authors who have taken part in this study declare they do not have anything to disclose regarding funding from industry or conflict of interest with respect to this manuscript.
Authors’ contributions
BG and DB participated in the design of the study. BG and NN performed the research and analysed the data. BG was responsible for the statistical analyses. BG drafted the manuscript. DB critically revised the manuscript. All authors have read and approved the final manuscript.